Fountain Healthcare Partners

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Founded in 2015, Neurent Medical is a medical device company based in Galway, Ireland. It specializes in developing non-surgical treatments for chronic rhinitis using minimally invasive, hand-held radio-frequency devices.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Priothera is a clinical-stage biotechnology company developing orally administered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company focuses on reducing the egress of T cell subsets from lymphatic tissue to enhance the curative potential of allogeneic hematopoietic stem cell transplantation, enabling dual inhibition of graft-versus-host disease while strengthening graft-versus-leukemia effects. Its lead program, mocravimod, aims to improve outcomes for patients undergoing HSCT. Priothera was incorporated in 2020 and is based in Dublin, Ireland, with an additional location in Saint Louis, France.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Founded in 2015, Neurent Medical is a medical device company based in Galway, Ireland. It specializes in developing non-surgical treatments for chronic rhinitis using minimally invasive, hand-held radio-frequency devices.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Inflazome Ltd. is a biotechnology company based in Dublin, Ireland, established in 2016. The company specializes in developing orally available drugs aimed at addressing unmet clinical needs in inflammatory diseases by targeting inflammasomes, which are critical in the inflammatory process. Inflazome's innovative therapies are designed to block inflammasome signals, thereby addressing the root causes of inflammation. The company's portfolio includes treatments for a range of conditions, such as neurological disorders like Alzheimer's and Parkinson's, systemic inflammatory diseases, and certain orphan diseases. As of September 2020, Inflazome operates as a subsidiary of Roche Holding AG, further enhancing its capacity to deliver targeted therapies in the field of inflammatory diseases.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.

Neuromod Devices, established in 2010 and headquartered in Dublin, Ireland, is a medical device company dedicated to the research and development of neuromodulation treatments for chronic tinnitus. The company's core product, the Mutebutton, is a bi-modal neuromodulation device designed to promote positive therapeutic changes in the human nervous system. Neuromod's mission is to empower patients worldwide, including the 10% of adults affected by chronic tinnitus, by delivering targeted, non-invasive therapies that seamlessly integrate into daily life.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Mainstay Medical is a medical device company focused on developing and commercializing ReActiv8, an implantable neurostimulation system designed to treat chronic mechanical low back pain by restoring control to the lumbar stabilizing muscles. Headquartered in Dublin, Ireland, it operates in Ireland, the United States, and Australia and collaborates with scientists and clinical experts to deliver therapies for the large underserved population of people with debilitating chronic low back pain. Founded in 2008, the company aims to provide a restorative treatment that improves function and quality of life by reestablishing muscle control in the lumbar spine.

Neuravi Limited, established in 2009 and based in Galway, Ireland, specializes in designing and developing medical devices for treating acute ischemic strokes. The company's primary product, the EmboTrap revascularization device, is designed to restore blood flow by removing clots from blocked brain arteries. Neuravi operates in multiple European countries and is a subsidiary of DePuy Ireland Unlimited Company.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Genable Technologies Limited is a bio-pharmaceutical company based in Dublin, Ireland, specializing in the development of gene therapies for autosomal dominant genetic diseases. The company focuses on innovative treatments for inherited disorders, notably its RhoNova product aimed at addressing rhodopsin (RHO)-linked autosomal dominant retinitis pigmentosa, a progressive form of inherited blindness caused by mutations in the RHO gene. Genable employs a unique approach that combines suppression and replacement of faulty gene copies using adeno-associated virus (AAV) vectors to deliver RNA interference (RNAi) molecules. This method allows the company to tackle the variability of mutations in dominant diseases without the need to target specific mutations. Genable Technologies was incorporated in 1998 and operates as a subsidiary of Spark Therapeutics, Inc. The company's technology is backed by a comprehensive portfolio of patents in the United States, Europe, and globally.

Amarin is a biopharmaceutical company focused on cardiovascular health, developing and commercializing therapeutics to reduce cardiovascular risk. Its lead product is Vascepa, a prescription omega-3 fatty acid capsule indicated to lower triglyceride levels in adults when used with diet, with development efforts including the REDUCE-IT program for patients with high triglycerides on statin therapy. The firm concentrates on lipid science and the therapeutic benefits of polyunsaturated fatty acids. It markets products primarily through wholesalers and specialty pharmacies via direct sales and maintains collaborations, including a development partnership with Mochida Pharmaceutical Co. Ltd. for products based on the active omega-3 ingredient in Vascepa. The company is headquartered in Dublin, Ireland, with research and development activities in Mystic, Connecticut, and was established in 1989 after formerly being named Ethical Holdings plc.

Cappella, Inc., a Dover, Del.- and Galway, Ireland-based medical device company that is developing novel solutions for the treatment of Complex Coronary Artery Disease (CAD) and specifically bifurcation vascular disease. The company was founded in 2004 by Antonio Columbo, M.D., Chief of Invasive Cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, M.D., Ph.D., a cardiologist, medical device entrepreneur and founder of NeoVision, Xcardia and Labcoat Ltd., and established its European headquarters in Galway in 2005.

Opsona Therapeutics is a Dublin-based drug development company specializing in immunology, particularly the modulation of innate immunity pathways. Founded in 2004, the company has developed innovative therapeutic approaches aimed at treating autoimmune and inflammatory diseases, as well as cancer. By targeting the innate immune system, Opsona addresses a spectrum of significant health challenges, including transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. The company seeks to improve patient outcomes through its novel drug candidates and strategies, positioning itself as a leader in emerging immunology research and drug development in Europe.

Vivasure Medical Limited is a medical device company based in Galway, Ireland, that specializes in the research, development, and manufacture of arterial and venous closure devices utilizing its patented PerQseal technology. The company focuses on creating polymer implants and delivery systems aimed at minimally invasive vessel closures, primarily in cardiology, interventional radiology, and vascular surgery. Its flagship product is an absorbable patch-based large-bore percutaneous closure device, designed to effectively close large arteriotomies resulting from transcatheter procedures, including transcatheter aortic valve replacement and endovascular aneurysm repair. Founded in 2008, Vivasure Medical is committed to advancing techniques that enhance patient outcomes in vascular access procedures.